



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION  
IAP7 Rec'd PCT/PTO 24 MAR 2006  
PC

re the Application of

Masao MORI et al.

Application No.: 10/557,922

Filed: December 22, 2005

Docket No.: 126068

For: COMPOUNDS AND PREPARATIONS HAVING ANTIVIRAL EFFECT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 2. Relevance of one or more non-English language reference is discussed in the present specification. See References 2-13 and 16.
- 3. One or more reference cited herein was cited in the International Search Report. An English language version of the International Search Report is attached for the Examiner's information. See References 1 and 14-20.
- 4. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.
- 5. An English language Abstract of one or more non-English language reference is attached hereto. See References 2-14.

6. A computer-generated English language translation of one or more Japanese Patent Publication cited herein has been obtained from the website of the Japanese Patent Office ([<http://www.jpo.go.jp>]), and is attached, but has not been reviewed for accuracy. See References 2-13.

Respectfully submitted,



James A. Oliff  
Registration No. 27,075

Randi B. Isaacs  
Registration No. 56,046

JAO:RBI/ojq

Date: March 24, 2006

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

<b>DEPOSIT ACCOUNT USE AUTHORIZATION</b> Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--



Form PTO-1449 (REV. 1/06) <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				US Dept. of Commerce PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. 126068	APPLICATION NO. 10/557,922
				<b>APPLICANTS</b> Masao MORI et al.		
				<b>FILING DATE</b> December 22, 2005		
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials	Cite No.	Document Number	Date	Name		
	1.	6,268,395 B1	07/31/2001	Masao HATTORI		
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation
	2.	JP-A-05-279329	10/26/1993	JAPAN	X	X
	3.	JP-A-05-331067	12/14/1993	JAPAN	X	X
	4.	JP-A-06-025158	02/01/1994	JAPAN	X	X
	5.	JP-A-06-073004	03/15/1994	JAPAN	X	X
	6.	JP-A-07-285877	10/31/1995	JAPAN	X	X
	9.	JP-A-09-030974	02/04/1997	JAPAN	X	X
	9.	JP-A-11-322789	11/24/1999	JAPAN	X	X
	9.	JP-A-05-097888	04/20/1993	JAPAN	X	X
	10.	JP-A-06-056825	03/01/1994	JAPAN	X	X
	10.	JP-A-06-234641	08/23/1994	JAPAN	X	X
	12.	JP-A-06-316524	11/15/1994	JAPAN	X	X
	13.	JP-A-07-082292	03/28/1995	JAPAN	X	X
	14.	WO 01/82927 A1	11/08/2001	WIPO	X	
<b>OTHER DOCUMENTS</b>						
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)				
	15.	EL-MEKKAWY et al., "Inhibition of Cytopathic Effect of Human Immunodeficiency Virus Type-1 by Various Phorbol Derivatives," Chem. Pharm. Bull., 2002, Vol. 50, No. 4, pp. 523-529				
	16.	EL-MEKKAWY et al., "12-O-Acetylphorbol-13-decanoate Potently Inhibits Cytopathic Effects of Human Immunodeficiency Virus Type 1 (HIV-1), without Activation of Protein Kinase C," Chem. Pharm. Bull., 1999, Vol. 47, No. 9, pp. 1346-1347				
	17.	EL-MEKKAWY et al., "Anti-HIV-1 phorbol esters from the seeds of <i>Croton tiglium</i> ," Phytochemistry, 2000, Vol. 53, No. 4, pp. 457-464				
	18.	MAIO et al., "Regulation of Expression Driven by Human Immunodeficiency Virus Type 1 and Human T-Cell Leukemia Virus Type 1 and Human T-Cell Leukemia Virus Type I Long Terminal Repeats in Pluripotential Human Embryonic Cells," J. Virol., 1988, Vol. 62, No. 4, pp. 1398-1407				
	19.	KINZEL et al., "Stimulation of Choline Incorporation in Cell Cultures by Phorbol Derivatives and Its Correlation with Their Irritant and Tumor-Promoting Activity," Cancer Research, 1979, Vol. 39, No. 7, pp. 2743-2750				
	20.	Chem. Abstr., Vol. 70, No. 4, 1969, pp. 359-360, abstract no. 70: 47626, KREIBICH et al. "Chemistry of Phorbol. V. Phorbol Ethers," Chemie, Biochemie. Biophysik. Biologie., 1968, Vol. 23, No. 11, pp. 1444-1452				
EXAMINER					DATE CONSIDERED	
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Date: March 24, 2006